|

Impact of Endo-vac Therapy for Esophago-jejunal Anastomotic Leak

RECRUITINGSponsored by Ukrainian Society of Clinical Oncology
Actively Recruiting
SponsorUkrainian Society of Clinical Oncology
Started2025-12-01
Est. completion2030-12-01
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07295236

Summary

The goal of this observational study is to assess the impact of endoscopic vacuum therapy in patients who underwent total gastrectomy due to gastric cancer and developed esophago-jejunal anastomotic leakage. The main outcomes to be investigated are the following: Primary endpoint: mortality rate Secondary endpoints: morbidity rate, time from AL diagnosis to discharge, patients satisfactory rate.

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* patients who developed esophago-jejunal anastomotic leak less than 50% of circumference of anastomosis
* patients who developed esophago-jejunal anastomotic leak and remained stable at the moment of diagnosis with no indications for diversion surgery

Exclusion Criteria:

* unstable patients who developed esophago-jejunal anastomotic leak
* patients who developed esophago-jejunal anastomotic leak more than 50% or anastomotic circumference
* patients who rejected endoscopic vacuum therapy

Conditions2

CancerEsophagojejunal Anastomotic Leak

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.